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Among all the leading causes of mortality worldwide, cancer
is responsible for approx. one in six deaths, and global cancer
data show that the cancer burden has recently risen to 18.1
million people [1]. This represents a demanding challenge
for healthcare systems and governments, whose actions are
increasingly aimed at developing commitments for cancer
treatment, on one hand, as well as at strengthening research
activities on the mechanisms of carcinogenesis and cancer
progression, on the other hand.
Fortunately, over the last decades, therapeutic strategies
against cancer have taken signiﬁcant steps forward, as dem-
onstrated by the fact that age-standardized cancer death rates
are falling globally [2]. However, medical treatments for
oncological patients still encounter signiﬁcant obstacles due
to the development of radio- and chemoresistance, which,
along with metastatic behavior, is thought to require exten-
sive reprogramming of mitochondrial activity [3]. The bal-
ance of ﬁssion and fusion, along with the regulation of
traﬃcking and autophagic removal, dictates mitochondrial
morphology and function [4], and some researchers have
suggested that mitochondrial dynamics could have a deep
impact on redox homeostasis and antioxidant defense of can-
cer cells, as well as on their apoptotic response to oxidative
stress-generating and DNA-damaging anticancer drugs [5].
This special issue comprises 4 review articles and 6
research articles that either investigated the role of mitochon-
dria in mediating the proapoptotic response of malignant
cells to anticancer drugs or examined ROS-dependent eﬀects
on redox-sensitive pathways controlling proliferation or
viability of cancer cells.
Mitochondrial dynamics is in part regulated by the Liver
Kinase B1- (LKB1-) AMP-activated protein kinase (AMPK)
pathway [6]. LKB1 was identiﬁed as the critical upstream
kinase required for AMPK activation thus providing a direct
link between a known tumor suppressor and the regulation
of metabolism. In fact, AMPK has a central role in the regu-
lation of energy metabolism and coordinates glucose and
lipid metabolism in response to alterations in nutrients and
intracellular energy levels, contributing to maintain steady-
state levels of intracellular ATP [7].
In their review article, F. Ciccarese et al. reported that loss
of LKB1-AMPK signalling is able to confer sensitivity to
energy depletion and to redox homeostasis impairment.
Moreover, the authors have found an association between
such a pathway and improved outcome in patients aﬀected
by advanced non-small-cell lung cancer (NSCLC) and
treated with chemotherapy.
In this context, the review article of B. Poljsak et al.
focused on the importance of understanding the origins of
cancer in order to ﬁnd successful strategies for eﬀective
cancer prevention and management.
In fact, it remains to be elucidated what exactly triggers
the reprogrammedmetabolism in cancer cells, and additional
studies are needed to extend the knowledge about the rela-
tionships between metabolic abnormalities and the occur-
rence of genetic mutations in cancer.
Hindawi
Oxidative Medicine and Cellular Longevity
Volume 2019, Article ID 4647807, 4 pages
https://doi.org/10.1155/2019/4647807
As reviewed by B. Marengo et al., the metabolic repro-
gramming is the result of a complex network of mechanisms
that, through the activation of oncogenes (i.e., MYC, HIF1,
and PI3K) or the downregulation of tumor suppressors
(i.e., TP53), induce an increased expression of glucose
and/or glutamine transporters, along with an overexpres-
sion of glycolytic enzymes. The authors reported that
among oncogenes, MYC is strongly involved in regulating
cell metabolism since it facilitates glycolysis by inducing
the activation of genes encoding for glycolytic enzymes
and it is also able to promote mitochondrial biogenesis
and function, thus increasing both oxygen consumption
and ATP production.
In addition, it has been postulated that mitochondrial
dysfunction in cancer cells would aﬀect the cellular ATPase
activities, ATP production, and subsequent apoptosis and
migration processes [8].
In their research article, X. Zhang et al. demonstrated that
the small molecule b-AP15 is an inhibitor of proteasome-
associated deubiquitinase activity, which induced an increase
in the generation of reactive oxygen species (ROS) in cancer
cells. Oxidative stress (OS) induced by b-AP15 was found to
be associated with a mitochondrial impairment and contrib-
uted to overcome resistance to bortezomib, which is an
inhibitor of the 20S proteasome, in the clinical management
of multiple myeloma.
Moreover, X. Li et al. have shown that KillerRed targeting
mitochondria (mtKR) aggravated the mitochondrial dys-
function induced by radiation, thus suggesting a new strategy
for ROS sensitization in future clinical cancer therapy. In this
study, the N-terminal mitochondrial-targeting sequence
(MTS) of PTEN-induced putative kinase 1 (Pink1) was used
to mediate downstream mCherry and KillerRed to express in
mitochondria, and the colocalization of mCherry (red) and
mitochondrial tracker COX IV (green) was observed by
ﬂuorescence microscope analysis in COS-7 cells and human
cervical cancer HeLa cells. In addition, the authors demon-
strated in HeLa cells transfected with mtKR plasmids that
mtKR induced mitochondrial ROS production, thus contrib-
uting to enhance apoptosis via the Cyt c/caspase-3 pathway
in tumors treated with radiation.
Interestingly, evidence shows that natural molecules,
such as curcumin and sulforaphane, are able to modulate
the response of cancer cells to anticancer therapies. However,
limited reports support the role of mitochondrial reprogram-
ming in such a phenomenon, even though several natural
chemosensitizers may act as regulators of mitochondrial
dynamics and function. Further investigations on this may
pave the way to diet-based approaches aimed at repressing
the adaptive responses involving mitochondria following
chemotherapy, thus contributing to an increase in the eﬃ-
cacy of anticancer strategies.
In their research article, B. George and H. Abrahamse,
from University of Johannesburg, demonstrated that
two phytochemicals isolated from roots of Rubus fairhol-
mianus (1-(2-hydroxyphenyl)-4-methylpentan-1-one and
2-[(3-methylbutoxy) carbonyl] benzoic acid) were able to
induce in human breast cancer MCF-7 cells an increase in
ROS formation, cytochrome c release, and changes in mito-
chondrial membrane potential (MMP), thus activating the
intrinsic apoptotic pathway. With speciﬁc focus on
mitochondrion-dependent processes, the authors have quan-
titatively detected cytochrome c release by ELISA, as well as
MMP by ﬂow cytometry with a JC-1-based ﬂuorescent kit.
The involvement of mitochondria in phytochemical-
induced death response in cancer cells was even more evident
in the original study of C. Antognelli et al., who identiﬁed in
non-small-cell lung cancer (NSCLC) cells an interesting
apoptogenic action of oleuropein (OP), a bioactive polyphe-
nol found in olives. The authors found that OP was able to
cause apoptotic death in A549 cells through depletion of
mitochondrial superoxide anion, which in turn inhibited
Akt signalling and activated the intrinsic apoptotic pathway
via mitochondrial glyoxalase 2- (mGlo2-) mediated interac-
tion with the proapoptotic protein Bax. This latter aspect is
one of the most interesting ﬁndings of the work. In fact, the
data provided by C. Antognelli et al. support the intriguing
hypothesis that glyoxalase 2, an enzyme that is convention-
ally considered an enzyme committed to downregulate the
formation of advanced glycation end products (AGEs) [9],
is also able to form protein adducts with apoptosis-related
factors. The critical role of mitochondrial redox reprogram-
ming in the processes summarized above was demonstrated
by silencing the mitochondrial superoxide dismutase
(SOD2). This restored the normal O2
⋅- levels and mGlo2
expression, and in such conditions, OP failed to induce apo-
ptosis in cancer cells. The interest for OP in terms of clinical
application is increased since the authors demonstrated that
OP did not aﬀect the viability of cells derived from human
normal bronchial epithelium.
The demand for anticancer drugs with low systemic
adverse eﬀects and low impact on healthy cells is highly
appreciated. In this context, the work from Y. Zheng et al.
(Guangzhou University, China) presented novel molecular
targets of betulinic acid (BA), a pentacyclic triterpene derived
from birch bark extracts. BA is attracting increasing attention
due to its high selectivity for cancer cells, with no apparent
systemic toxicity in mice [10, 11]. BA proapoptotic eﬀects
in malignant cells have been traditionally linked to mito-
chondrial ROS generation and induction of DNA damage
[12, 13]; however, Y. Zheng et al. revealed that BA attenuated
migration and invasion of highly aggressive breast cancer
cells via aerobic glycolysis inhibition, and glucose-regulated
protein (GRP78), a major chaperone in the endoplasmic
reticulum, was found to be critical for inhibitory eﬀects of
BA on glycolytic proteins. Moreover, Y. Zheng et al.’s ﬁnd-
ings indicated that the oxygen consumption rate (OCR) of
breast cancer cell lines MDA-MB-231 and BT-549 decreased
following BA treatment, thus suggesting that BA switched
the cells from an energetic metabolic state to a relatively
quiescent state. In their experiments, the authors obtained
accurate proﬁles of cancer cell energy phenotypes by
using a live cell metabolic assay platform for extracellular
ﬂux analyses.
The crucial roles of ROS scavenging systems and
mitochondria in triggering the cancer cell death induced by
dietary polyphenols have been extensively reviewed and
summarized by S. NavaneethaKrishnan et al. In their review,
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the authors focused their attention on some of the best
known vegetable- and fruit-derived polyphenols with recog-
nized pro-death properties against cancer cells. In particular,
in their paper, S. NavaneethaKrishnan et al. provided inter-
esting information about the cytotoxic eﬀects of quercetin,
curcumin, and resveratrol, with particular attention to the
activation of ROS- and mitochondrion-dependent molecular
pathways as possible mediators of such eﬀects. In some
cases, the redox-dependent cancer cell death is promoted
through the activation of ROS-induced apoptosis, MMP
reduction, cytochrome C release, and subsequent activation
of caspase-3. In other cases, these polyphenols enhance
TNF-related apoptosis-inducing ligand- (TRAIL-) induced
apoptosis via the inhibition of ERK signalling pathway or by
oxidatively modifying proteins that belong to the mitochon-
drial permeability transition pore (mPTP), thus causingmito-
chondrial depolarization, inhibition of ATP synthesis, and
cell death. Furthermore, it was reported that some common
plant-derived polyphenols exhibit a marked ROS-inducing
capacity that leads to mitochondrial DNA damage and
impairment of mitochondrial oxidative phosphorylation
(OXPHOS). In addition, beyond exerting clear proapoptotic
actions, some dietary polyphenols have also been proven
to act as cell cycle arresting factors. Finally, the authors
provided some interesting information about redox- and
mitochondrion-targeting anticancer properties of less famous
dietary polyphenols, such as capsaicin, coumaric acid, and
phenethyl isothiocyanate, which leads to mitochondrial
dysfunction in cancer cells but not in normal cells. Lastly,
since poor absorption and fast metabolism of dietary poly-
phenols are concerning limiting factors in the administra-
tion to humans, promising strategies that include the use
of novel formulations, prodrugs, and innovating delivery
systems are proposed.
Hence, any strategy aimed at increasing ROS production
or diminishing antioxidant capacity should be seen as a
potential means by which the abnormal proliferation and
growth of malignant cancer cells could be prevented or
delayed. This topic was further investigated in the paper from
K. Chen et al., who demonstrated that by deleting bloom
syndrome protein (BLM), a DNA helicase belonging to
the RecQ family, the proliferation of prostate cancer
(PC) cells was repressed via downregulation of AKT sig-
nalling, and this was accompanied by enhanced ROS pro-
duction. Of note, in their research, the authors used state-
of-the-art techniques, such as isobaric tags for relative and
absolute quantiﬁcation (iTRAQ) proteomics, CRISPR/-
Cas9-mediated gene editing, and automated western blot
quantitative analysis.
We sincerely hope that the articles oﬀered by this special
issue may provide interesting mechanistic insights of the
role of mitochondria and redox-related signalling pathways
in determining the cancer metabolic reprogramming, the
proliferative activity of cancer cells, or their apoptotic
response to exogenous stressors (e.g., natural anticancer
molecules). We also strongly hope that further eﬀorts will
be spent for expanding the scientiﬁc knowledge on such
topics, with the aim of future development of diet-based
co-therapies for cancer.
Finally, we wish to thank all the authors for sharing their
novel ﬁndings or reviews, and all reviewers for their priceless
support in processing all the manuscripts.
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